A chronic lung infection with Pseudomonas aeruginosa is associated with an increased exacerbation and mortality rate in people affected by bronchiectasis. Inhaled antibiotics are frequently used in clinical practice to treat chronic infections with this bacterium. The PROMIS-I and PROMIS-II studies investigated the efficacy and safety of 12-month inhaled colistimethate sodium administration in patients with bronchiectasis and chronic P. aeruginosa infection.
Autoren
- Jens Dehn
Publikation
- InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
You May Also Like
- From symptom to diagnosis
Oncology – Thymoma
- Shared decision making
Participatory decision-making using the example of diets for type 1 diabetes
- Patient-centered rounds in medicine
Aligning care with the patient
- Migraine and vascular regulation
CGRP-targeted migraine therapies for vascular risk patients
- Pediatric multiple sclerosis
Early high efficacy as the key to improving prognosis
- Case report, molecular basis and therapeutic implications
HER2-positive colorectal carcinoma with invasive micropapillary component
- Wound Care
Chronically infected wound on the lower leg – a case report
- From symptom to diagnosis